All agree that good patient adherence to their treatment regime is critical. However, a number of patients decide not to take their medicines as directed. The direct and consequential cost and health impacts of poor patient adherence are considerable, but changing behaviour is proving a challenge. For deep background research and critical insights to tackle this issue turn to this new report. Learn more.
Bayer Healthcare on Monday announced that it entered into an exclusive license agreement with Isis Pharmaceuticals to develop and commercialise the experimental Factor XI inhibitor ISIS-FXI for the... Read More >>